follicular lymphoma

News

Representation on cellular level of lymphoma

Approvals extend use of Roche, AbbVie drugs in lymphoma

Patients in the US and EU with follicular lymphoma have new treatment options, thanks to new approvals for CD20xCD3 bispecifics Lunsumio and Epkinly.

News

Regeneron tries again with lymphoma bispecific in US

Regeneron has refiled its CD20xCD3 bispecific odronextamab for lymphoma with the FDA, which was rejected last year, but is seeking a narrower label.

News

After FDA no, Regeneron gets yes from EU on odronextamab

Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US.

News

FDA clears BMS’ Breyanzi for follicular lymphoma

Bristol-Myers Squibb has chalked up another FDA approval for its CD19-directed CAR-T therapy Breyanzi, this time as a third-line or later therapy for follicular lymphoma (

News

FDA turns down Regeneron bispecific blood cancer antibody

The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL).

News

Micrograph showing a small B-cell lymphoma compatible with follicular lymphoma

BeiGene breaks new ground for BTK drugs in blood cancers

BeiGene’s BTK inhibitor Brukinsa has become the first drug in the class to be approved in the US for follicular lymphoma, giving it the broadest label among its rivals.

Approvals extend use of Roche, AbbVie drugs in lymphoma

Regeneron tries again with lymphoma bispecific in US

After FDA no, Regeneron gets yes from EU on odronextamab

FDA clears BMS’ Breyanzi for follicular lymphoma

FDA turns down Regeneron bispecific blood cancer antibody

BeiGene breaks new ground for BTK drugs in blood cancers

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

follicular lymphoma

Editor's Picks